SGHT Latest News, Press Relases and Analysis

All

Press Releases

15 days ago - By: Zacks Investment Research

Sight Sciences (SGHT) Upgraded to Buy: Here's What You Should Know

15 days ago - By: Sight Sciences, Inc.

New Peer-Reviewed Publications Highlight Effectiveness of OMNI® Surgical System with TruSync™ Technology in Reducing IOP and Medication Usage in Cataract Combination Procedures, Standalone Procedures, and in African Americans

20 days ago - By: Zacks Investment Research

Sight Sciences (SGHT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

20 days ago - By: Zacks Investment Research - Mentions: MASS

Sight Sciences, Inc. (SGHT) Reports Q3 Loss, Tops Revenue Estimates

20 days ago - By: The Motley Fool

Sight Sciences (SGHT) Q3 2025 Earnings Transcript

20 days ago - By: Benzinga - Mentions: STVN PODD AMRK SOLV ...

Earnings Scheduled For November 6, 2025

3 months ago - By: Benzinga

What 4 Analyst Ratings Have To Say About Sight Sciences

20 days ago - By: Sight Sciences, Inc.

Sight Sciences Reports Third Quarter 2025 Financial Results and Raises Full Year 2025 Revenue Guidance

20 days ago - By: Sight Sciences, Inc.

Sight Sciences Appoints Ali Bauerlein as Chief Operating Officer and Jim Rodberg as Chief Financial Officer

21 days ago - By: Zacks Investment Research - Mentions: STE

Steris (STE) Surpasses Q2 Earnings and Revenue Estimates

22 days ago - By: Sight Sciences, Inc.

Sight Sciences to Present at Two Upcoming Investor Conferences

a month ago - By: Sight Sciences, Inc.

Sight Sciences to Report Third Quarter 2025 Financial Results on November 6, 2025

a month ago - By: Sight Sciences, Inc.

Sight Sciences Announces Fee Schedule Establishment from Novitas Solutions and First Coast Service Options for the TearCare® Interventional Dry Eye Procedure

2 months ago - By: Sight Sciences, Inc.

Sight Sciences Announces Publication of a Systematic Literature Review and Meta-Analysis Showing OMNI® Surgical System Achieves Clinically Significant, Long-Term Reductions in IOP and Medication Use

3 months ago - By: Sight Sciences, Inc.

Sight Sciences Announces the OMNI® Surgical System to be Included in UnitedHealthcare’s® Expanded Coverage of Glaucoma Surgical Treatments

3 months ago - By: Sight Sciences, Inc.

Sight Sciences Announces Recognition of the TearCare® System in TFOS DEWS III Global Dry Eye Guidelines Published in AJO

3 months ago - By: Zacks Investment Research - Mentions: JNJ ALC GKOS

Glaukos Builds Dual Growth Engines Amid Market Headwinds

3 months ago - By: Sight Sciences, Inc.

Sight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference

4 months ago - By: Zacks Investment Research

Compared to Estimates, Sight Sciences (SGHT) Q2 Earnings: A Look at Key Metrics

4 months ago - By: Zacks Investment Research - Mentions: DRIO

Sight Sciences, Inc. (SGHT) Reports Q2 Loss, Tops Revenue Estimates

4 months ago - By: Zacks Investment Research - Mentions: VCYT

Veracyte (VCYT) Tops Q2 Earnings and Revenue Estimates

4 months ago - By: Sight Sciences, Inc.

Sight Sciences Announces the Results of a Cost-Utility Analysis Demonstrating Cost Savings and Greater Health Utility with the TearCare® System Compared to Cyclosporine 0.05% for Treating Meibomian Gland Disease-Associated Dry Eye Disease

4 months ago - By: Sight Sciences, Inc.

Sight Sciences Announces the Publication of the 24-Month Results of the SAHARA RCT Demonstrating the Durability of the TearCare® Procedure for the Treatment of Dry Eye Disease

4 months ago - By: Sight Sciences, Inc.

Sight Sciences to Report Second Quarter 2025 Financial Results on August 7, 2025

7 months ago - By: Zacks Investment Research

Sight Sciences (SGHT) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

7 months ago - By: Zacks Investment Research - Mentions: CLPT

Sight Sciences, Inc. (SGHT) Reports Q1 Loss, Tops Revenue Estimates

7 months ago - By: Sight Sciences, Inc.

Sight Sciences Reports First Quarter 2025 Financial Results and Reaffirms Full Year 2025 Revenue Guidance

7 months ago - By: Sight Sciences, Inc.

Sight Sciences Reports First Quarter 2025 Financial Results and Reaffirms Full Year 2025 Revenue Guidance

7 months ago - By: Zacks Investment Research - Mentions: AORT

Artivion (AORT) Lags Q1 Earnings Estimates

7 months ago - By: Sight Sciences, Inc.

SIGHT SCIENCES INC (SGHT) Stock News

SGHT Latest News, Press Relases and Analysis

Sight Sciences (SGHT) Upgraded to Buy: Here's What You Should Know

New Peer-Reviewed Publications Highlight Effectiveness of OMNI® Surgical System with TruSync™ Technology in Reducing IOP and Medication Usage in Cataract Combination Procedures, Standalone Procedures, and in African Americans

Sight Sciences (SGHT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

Sight Sciences, Inc. (SGHT) Reports Q3 Loss, Tops Revenue Estimates

Sight Sciences (SGHT) Q3 2025 Earnings Transcript

Earnings Scheduled For November 6, 2025

What 4 Analyst Ratings Have To Say About Sight Sciences

Sight Sciences Reports Third Quarter 2025 Financial Results and Raises Full Year 2025 Revenue Guidance

Sight Sciences Appoints Ali Bauerlein as Chief Operating Officer and Jim Rodberg as Chief Financial Officer

Steris (STE) Surpasses Q2 Earnings and Revenue Estimates

Sight Sciences to Present at Two Upcoming Investor Conferences

Sight Sciences to Report Third Quarter 2025 Financial Results on November 6, 2025

Sight Sciences Announces Fee Schedule Establishment from Novitas Solutions and First Coast Service Options for the TearCare® Interventional Dry Eye Procedure

Sight Sciences Announces Publication of a Systematic Literature Review and Meta-Analysis Showing OMNI® Surgical System Achieves Clinically Significant, Long-Term Reductions in IOP and Medication Use

Sight Sciences Announces the OMNI® Surgical System to be Included in UnitedHealthcare’s® Expanded Coverage of Glaucoma Surgical Treatments

Sight Sciences Announces Recognition of the TearCare® System in TFOS DEWS III Global Dry Eye Guidelines Published in AJO

Glaukos Builds Dual Growth Engines Amid Market Headwinds

Sight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference

Compared to Estimates, Sight Sciences (SGHT) Q2 Earnings: A Look at Key Metrics

Sight Sciences, Inc. (SGHT) Reports Q2 Loss, Tops Revenue Estimates

Veracyte (VCYT) Tops Q2 Earnings and Revenue Estimates

Sight Sciences Announces the Results of a Cost-Utility Analysis Demonstrating Cost Savings and Greater Health Utility with the TearCare® System Compared to Cyclosporine 0.05% for Treating Meibomian Gland Disease-Associated Dry Eye Disease

Sight Sciences Announces the Publication of the 24-Month Results of the SAHARA RCT Demonstrating the Durability of the TearCare® Procedure for the Treatment of Dry Eye Disease

Sight Sciences to Report Second Quarter 2025 Financial Results on August 7, 2025

Sight Sciences (SGHT) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Sight Sciences, Inc. (SGHT) Reports Q1 Loss, Tops Revenue Estimates

Sight Sciences Reports First Quarter 2025 Financial Results and Reaffirms Full Year 2025 Revenue Guidance

Sight Sciences Reports First Quarter 2025 Financial Results and Reaffirms Full Year 2025 Revenue Guidance

Artivion (AORT) Lags Q1 Earnings Estimates

Sight Sciences to Report First Quarter 2025 Financial Results on May 8, 2025